Accelerate Diagnostics AXDX
AXDX is a one-product company whose Pheno system is a flawed niche diagnostic — missed reagent targets, a looming Mayo-UCLA study failure, and cash burn point to 70% downside to a $6 price target.
Thesis
White Diamond argues Accelerate Diagnostics (AXDX), priced at ~$1B market cap after a 70% YTD rally, is a one-product company whose PhenoTest is a niche adjunct rather than a replacement for standard cell-culture diagnostics. Proprietary reseller interviews at ECCMID 2019 (BioMerieux, ThermoFisher, Beckman Coulter) and peer-reviewed literature show the Pheno fails in ~27% of runs, covers only 16 organisms, and delivers a ~40% (not 75%) time advantage over MALDI+BD Phoenix. Management has quietly walked back reagent-revenue-per-system guidance from $60K-$80K to $45K-$65K and lengthened the install lag from 3-4 to 4-9 months. With the Mayo-UCLA study likely failing to show LOS or mortality improvement, $20M quarterly losses, a cash runway of six quarters, and a new COO (Jack Phillips) likely replacing CEO Larry Mehren, fair value is $200M-$300M — a $6 price target and 70% downside.
SCQA
Accelerate Diagnostics (AXDX) is a one-product rapid-sepsis diagnostic company whose Pheno system is priced at a ~$1B market cap after a 70%+ YTD rally, with investors betting on standard-of-care adoption.
The Pheno is a narrow adjunct that fails in 27% of runs, covers only 16 organisms, and missed reagent-revenue-per-system targets by 30%; management has already walked back guidance twice.
Short AXDX ahead of the October Mayo-UCLA readout — which will fail to show length-of-stay or mortality improvement — and a likely CEO change and guidance reset.
Fair value is $200M-$300M, implying a $6 price target and roughly 70% downside over the next 6-9 months as reagent revenues, cash burn, and clinical data disappoint.
The three reasons
- 1
Pheno system is a niche adjunct, not a replacement for cell-culture tests
- 2
Reagent revenue per system missed management's target by over 30%
- 3
Mayo-UCLA study will not show improvement in length-of-stay or mortality
Primary demands
- Short AXDX with a $6 price target (~70% downside)
- Fair market value should be $200M-$300M, not ~$1B
KPIs cited
Pattern membership
Precedents cited
- BioFire Mayo group study (underpowered, failed primary endpoint)
- Jack Schuler's prior 10% stakes (YTEN, CAPN, VRML, BIOL, NEOS — mostly negative 5-yr returns)
Composition what's on the 39 slides
Slide gallery ·
Notes
Prose-style short-seller research note (Word-doc layout with inline tables and pasted chart screenshots) rather than a slide deck. White Diamond is the firm credit; no individual author named on cover. Strong SCQA: opens with 5 bullet takeaways and $6 price target on page 1, closes with $200M-$300M fair value on page 41. Heavy use of CEO-quote contradictions (Mehren Q1 18 vs Q2 19 on reagent revenue and Mayo-UCLA expectations) and primary-source reseller interviews at ECCMID 2019. Peer benchmarking vs MALDI+BD Phoenix is a clean before/after timeline visual. No stake disclosure — short-seller report.